Today March 28 the Swedish market close at 13.00. Danish and Norweigan markets is closed.

PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
-0.055
%
−7,05%
Latest
0.725
High
0.725
Low
0.72
Volume
580
Turnover (SEK)
418
Market Value (MSEK)
30,6
Time (Latest trade)
2024-03-28 10:54

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 50,47 50,47 2024-03-18
Vict Th Engwalls Stiftelse 2,30 2,30 2023-12-27
Avanza Pension 1,67 1,67 2023-12-27
Arne Arvidsson 1,44 1,44 2023-12-27
Nordnet Pensionsförsäkring 0,94 0,94 2023-12-27
Staffan Engelbert Bodén 0,60 0,60 2023-12-27
Henrik Skog 0,57 0,57 2023-12-27
Merrick Lee Tabor 0,54 0,54 2023-12-27
Mats Andersson 0,52 0,52 2021-12-31
Arne Skogvall 0,52 0,52 2023-12-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-05-16 Delårsrapport 2024-Q1

  • 2024-08-15 Delårsrapport 2024-Q2

  • 2024-11-21 Delårsrapport 2024-Q3

  • 2025-02-20 Bokslutskommuniké 2024